The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Rituximab, B-Lymphocyte Depletion, and Preservation of Beta-Cell Function
Open accessAbstract
BACKGROUND: The immunopathogenesis of type 1 diabetes mellitus is associated with T-lymphocyte autoimmunity. However, there is growing evidence that B lymphocytes play a role in many T-lymphocyte-mediated diseases. It is possible to achieve selective depletion of B lymphocytes with rituximab, an anti-CD20 monoclonal antibody. This phase 2 study evaluated the role of B-lymphocyte depletion in patients with type 1 diabetes. METHODS: We conducted a randomized, double-blind study in which 87 patients between 8 and 40 years of age who had newly diagnosed type 1 diabetes were assigned to receive infusions of rituximab or placebo on days 1, 8, 15, and 22 of the study. The primary outcome, assessed 1 year after the first infusion, was the geometric mean area under the curve (AUC) for the serum C-peptide level during the first 2 hours of a mixed-meal tolerance test. Secondary outcomes included safety and changes in the glycated hemoglobin level and insulin dose. RESULTS: At 1 year, the mean AUC for the level of C peptide was significantly higher in the rituximab group than in the placebo group. The rituximab group also had significantly lower levels of glycated hemoglobin and required less insulin. Between 3 months and 12 months, the rate of decline in C-peptide levels in the rituximab group was significantly less than that in the placebo group. CD19+ B lymphocytes were depleted in patients in the rituximab group, but levels increased to 69% of baseline values at 12 months. More patients in the rituximab group than in the placebo group had adverse events, mostly grade 1 or grade 2, after the first infusion. The reactions appeared to be minimal with subsequent infusions. There was no increase in infections or neutropenia with rituximab. CONCLUSIONS: A four-dose course of rituximab partially preserved beta-cell function over a period of 1 year in patients with type 1 diabetes. The finding that B lymphocytes contribute to the pathogenesis of type 1 diabetes may open a new pathway for exploration in the treatment of patients with this condition. (ClinicalTrials.gov number, NCT00279305.)
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Disappointingly, after promising phase 1–2 trials in patients with recent-onset type 1 diabetes and detectable endogenous insulin production, phase 3 trials of anti-CD3 antibodies (otelixizumab and teplizumab), and the Diamyd vaccine (GAD-alum immunotherapy) did not meet primary endpoints.135–141”
From Type 1 diabetes (2014) · cites this paper as [136]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“These drugs include a monoclonal antibody against the B-cell CD20 receptor (rituximab),147 monoclonal antibodies against the T-cell CD3 receptor (teplizumab148,149 and otelixizumab150), cytotoxic T-lymphocyte protein 4 (CTLA4)-immunoglobulin-mediated co-stimulatory blockade with abatacept,151 and alefacept,152”
From Type 1 diabetes (2018) · cites this paper as [147]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291401 · Cited by 24,667
B-cell depletion with rituximab in relapsing-remitting multiple sclerosis
Hauser, S. L., Waubant, E., Arnold, D. L., Vollmer, T., Antel, J., Fox, R. J., Bar-Or, A., Panzara, M., Sarkar, N., Agarwal, S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0706383 · Cited by 2,439
Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20
Reff, M., Carner, K., Chambers, K., Chinn, P., Leonard, J., Raab, R., Newman, R., Hanna, N., & Anderson, D. (1994) · Blood · doi:10.1182/blood.v83.2.435.435 · Cited by 1,996
Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus
Herold, K. C., Hagopian, W., Auger, J. A., Poumian-Ruiz, E., Taylor, L., Donaldson, D., Gitelman, S. E., Harlan, D. M., Xu, D., Zivin, R. A., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa012864 · Cited by 1,222
Self-citationInsulin needs after CD3-antibody therapy in new-onset type 1 diabetes
Keymeulen, B., Vandemeulebroucke, E., Ziegler, A. G., Mathieu, C., Kaufman, L., Hale, G., Gorus, F., Goldman, M., Walter, M., Candon, S., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043980 · Cited by 1,099
Davidson, A., & Diamond, B. (2001) · New England Journal of Medicine · doi:10.1056/nejm200108023450506 · Cited by 1,069
Emery, P., Fleischmann, R., Filipowicz‐Sosnowska, A., Schechtman, J., Szczepanski, L., Kavanaugh, A., Racewicz, A. J., van Vollenhoven, R., Li, N. F., Agarwal, S. K., et al. (2006) · Arthritis & Rheumatism · doi:10.1002/art.21778 · Cited by 1,061
(2006) · Elsevier eBooks · doi:10.1016/b978-0-12-595961-2.x5000-8 · Cited by 963
Looney, R. J., Anolik, J. H., Campbell, D., Felgar, R. E., Young, F. M., Arend, L. J., Sloand, J. A., Rosenblatt, J. D., & Sanz, I. (2004) · Arthritis & Rheumatism · doi:10.1002/art.20430 · Cited by 779
Rituximab, an Anti-CD20 Monoclonal Antibody: History and Mechanism of Action
Pescovitz, M. D. (2006) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2006.01288.x · Cited by 626
Self-citationT Cell Activation in Rheumatoid Synovium Is B Cell Dependent
Takemura, S., Klimiuk, P. A., Braun, A. B., Goronzy, J. J., & Weyand, C. M. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.167.8.4710 · Cited by 536
GAD treatment and insulin secretion in recent-onset type 1 diabetes
Ludvigsson, J., Faresjö, M., Hjorth, M., Axelsson, S., Chéramy, M., Pihl, M., Vaarala, O., Forsander, G., Ivarsson, S., Johansson, C., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0804328 · Cited by 520
Palmer, J. P., Fleming, G. A., Greenbaum, C. J., Herold, K. C., Jansa, L. D., Kolb, H., Lachin, J. M., Polonsky, K. S., Pozzilli, P., Skyler, J. S., et al. (2004) · Diabetes · doi:10.2337/diabetes.53.1.250 · Cited by 491
Self-citationSerologic changes following B lymphocyte depletion therapy for rheumatoid arthritis
Cambridge, G., Leandro, M. J., Edwards, J., Ehrenstein, M. R., Salden, M., Bodman‐Smith, M. D., & WEBSTER, A. D. B. (2003) · Arthritis & Rheumatism · doi:10.1002/art.11181 · Cited by 470
Risk Factors for Cyclosporine-Induced Nephropathy in Patients with Autoimmune Diseases
Feutren, G., & Mihatsch, M. J. (1992) · New England Journal of Medicine · doi:10.1056/nejm199206183262502 · Cited by 408
Piro, L. D., White, C. A., Grillo-López, A. J., Janakiraman, N., Saven, A., Beck, T., Varns, C., Shuey, S., Czuczman, M. S., Lynch, J. W., et al. (1999) · Annals of Oncology · doi:10.1023/a:1008389119525 · Cited by 368
Greenbaum, C. J., Mandrup-Poulsen, T. R., McGee, P. F., Battelino, T., Haastert, B., Ludvigsson, J., Pozzilli, P., Lachin, J. M., & Kolb, H. (2008) · Diabetes Care · doi:10.2337/dc07-2451 · Cited by 285
Self-citationB-Cells Are Required for the Initiation of Insulitis and Sialitis in Nonobese Diabetic Mice
Noorchashm, H., Noorchashm, N., Kern, J. H., Rostami, S. Y., Barker, C. F., & Naji, A. (1997) · Diabetes · doi:10.2337/diab.46.6.941 · Cited by 265
Rituximab treatment of idiopathic membranous nephropathy
Fervenza, F. C., Cosío, B. G., Erickson, S. B., Specks, U., Herzenberg, A. M., Dillon, J. J., Leung, N., Cohen, I. M., Wochos, D. N., Bergstralh, E. J., et al. (2007) · Kidney International · doi:10.1038/sj.ki.5002628 · Cited by 264
Development of Type 1 Diabetes despite Severe Hereditary B-Cell Deficiency
Martin, S., Wolf-Eichbaum, D., Duinkerken, G., Scherbaum, W. A., Kolb, H., Noordzij, J. G., & Roep, B. O. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa010465 · Cited by 253
Noorchashm, H., Lieu, Y. K., Noorchashm, N., Rostami, S. Y., Greeley, S. A. W., Schlachterman, A., Song, H. K., Noto, L. E., Jevnikar, A. M., Barker, C. F., et al. (1999) · PubMed · Cited by 229
Kim, H. J., Krenn, V., Steinhauser, G., & Berek, C. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.162.5.3053 · Cited by 218
Immunologic responses to bacteriophage ϕX 174 in immunodeficiency diseases
Ochs, H. D., Davis, S. D., & WEDGWOOD, R. J. P. (1971) · Journal of Clinical Investigation · doi:10.1172/jci106756 · Cited by 217
Noorchashm, H., Lieu, Y. K., Noorchashm, N., Rostami, S. Y., Greeley, S. A. W., Schlachterman, A., Song, H. K., Noto, L. E., Jevnikar, A. M., Barker, C. F., et al. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.163.2.743 · Cited by 211
Genovese, M. C., Kaine, J., Lowenstein, M. B., Giudice, J. D., Baldassare, A. R., Schechtman, J., Fudman, E. J., Kohen, M. D., Gujrathi, S., Trapp, R. G., et al. (2008) · Arthritis & Rheumatism · doi:10.1002/art.23732 · Cited by 208
Rivera, A., Chen, C.-C., Ron, N., Dougherty, J. P., & Ron, Y. (2001) · International Immunology · doi:10.1093/intimm/13.12.1583 · Cited by 200
Lapointe, R., Bellemare‐Pelletier, A., Housseau, F., Thibodeau, J., & Hwu, P. (2003) · PubMed · Cited by 189
(2004) · Diabetes · doi:10.2337/diabetes.53.7.1934 · Cited by 120
Cattaneo, C. M., Spedini, P., Casari, S., Re, A., Tucci, A., Borlenghi, E., Ungari, M., Ruggeri, G. M., & Rossi, G. (2006) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428190500473113 · Cited by 116
B-cells are required for the initiation of insulitis and sialitis in nonobese diabetic mice
Noorchashm, H., Noorchashm, N., Kern, J. H., et al. (1997) · Diabetes · doi:10.2337/diabetes.46.6.941 · Cited by 102
Bearden, C. M., Agarwal, A., Book, B. K., Vieira, C. A., Sidner, R. A., Ochs, H. D., Young, M., & Pescovitz, M. D. (2005) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2003.00646.x · Cited by 93
Self-citationMixed Models: Theory and Applications (Wiley Series in Probability and Statistics)
Demidenko, E. (2004) · Wiley-Interscience eBooks · Cited by 76
Rituximab, Anti-CD20, Induces In Vivo Cytokine Release But Does Not Impair Ex Vivo T-Cell Responses
Agarwal, A., Vieira, C. A., Book, B. K., Sidner, R. A., Fineberg, N. S., & Pescovitz, M. D. (2004) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2004.00502.x · Cited by 60
Self-citationSERREZE, D. V., & Silveira, P. A. (2002) · KARGER eBooks · doi:10.1159/000066863 · Cited by 55
The use of rituximab, anti‐CD20 monoclonal antibody, in pediatric transplantation
Pescovitz, M. D. (2004) · Pediatric Transplantation · doi:10.1046/j.1397-3142.2003.00135.x · Cited by 41
Self-citationThe Role of T/B Lymphocyte Collaboration in the Regulation of Autoimmune and Alloimmune Responses
Noorchashm, H., Greeley, S. A. W., & Naji, A. (2003) · Immunologic Research · doi:10.1385/ir:27:2-3:443 · Cited by 21
Lessons Learned from Use of Cyclosporine for Insulin‐Dependent Diabetes Mellitus
Mahon, J. L., DUPRE, J., & STILLER, C. R. (1993) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1993.tb17171.x · Cited by 20
Immunoprotection in spontaneous remission of type 1 diabetes: long-term follow-up results
Yilmaz, M. T., Devrim, A. S., Biyal, F., Satman, İ., Oral, E. A., Dınççağ, N., Karşıdağ, K., Özden, İ., Gürel, N., Sipahioğlu, F., et al. (1993) · Diabetes Research and Clinical Practice · doi:10.1016/0168-8227(93)90108-h · Cited by 11
Progress in the Immunointervention of Type-1 Diabetes Mellitus
Schernthaner, G. (1995) · Hormone and Metabolic Research · doi:10.1055/s-2007-980023 · Cited by 7
Flagged first, then by citations
Research works printed but not linked: 1
- Lapointe R, 2003, Cancer Res, 63, 2836
Cited by
Sorted by citations
Standards of medical care in diabetes—2013
American Diabetes Association (2013) · Diabetes Care · doi:10.2337/dc13-s011 · Cited by 4,369
Atkinson, M. A., Eisenbarth, G. S., & Michels, A. W. (2014) · The Lancet · doi:10.1016/s0140-6736(13)60591-7 · Cited by 2,931
DiMeglio, L. A., Evans-Molina, C., & Oram, R. A. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31320-5 · Cited by 1,561
Katsarou, A., Gudbjörnsdottir, S., Rawshani, A., Dabelea, D., Bonifacio, E., Anderson, B. J., Jacobsen, L. M., Schatz, D. A., & Lernmark, Å. (2017) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2017.16 · Cited by 1,475
Self-citationThe Role of Inflammation in Diabetes: Current Concepts and Future Perspectives
Tsalamandris, S., Antonopoulos, A. S., Oikonomou, E., Papamikroulis, G.-A., Vogiatzi, G., Papaioannou, S., Deftereos, S., & Tousoulis, D. (2019) · European Cardiology Review · doi:10.15420/ecr.2018.33.1 · Cited by 1,381
Metadata
- Authors
- Pescovitz, M. D., Greenbaum, C. J., Krause-Steinrauf, H., Becker, D. J., Gitelman, S. E., Goland, R., Gottlieb, P. A., Marks, J. B., McGee, P. F., Moran, A. M., Raskin, P., Rodriguez, H., Schatz, D. A., Wherrett, D., Wilson, D. M., Lachin, J. M., & Skyler, J. S.
- Affiliations
- Indiana University School of Medicine (US)
- Benaroya Research Institute (US)
- George Washington University (US)
- University of Pittsburgh (US)
- University of California, San Francisco (US)
- Columbia University (US)
- University of Colorado Health (US)
- University of Miami (US)
- University of Minnesota (US)
- The University of Texas Southwestern Medical Center (US)
- University of Florida (US)
- University of Toronto (CA)
- Stanford University (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2009-11-26
- Volume
- 361
- Issue
- 22
- Pages
- 2143-2152
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC6410357
- OpenAlex
- W2064431167
- Cited by
- 1,093
- References
- 39
- Citations by year
- 2026: 45 · 2025: 65 · 2024: 56 · 2023: 55 · 2022: 56 · 2021: 64 · 2020: 53 · 2019: 49 · 2018: 49 · 2017: 45 · 2016: 57 · 2015: 63 · 2014: 72 · 2013: 98 · 2012: 89
- FWCI
- 51.38
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- IUScholarWorks (Indiana University) (submittedVersion)
- Purdue University Indianapolis (Indiana University) (submittedVersion)
- PMC
- Funders
- American Diabetes Association
- Juvenile Diabetes Research Foundation International
- Eli Lilly and Company
- Biogen
- Osiris Therapeutics
- MacroGenics
- National Institutes of Health
- Genentech
- National Institute of Allergy and Infectious Diseases
- National Institute of Diabetes and Digestive and Kidney Diseases (R21DK077329, U01DK061058, U01DK061034, U01DK103282)
- National Institute of Child Health and Human Development
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Diabetes and associated disorders
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- rituximab, B-cell depletion, type 1 diabetes, beta-cell preservation, anti-CD20 monoclonal antibody, C-peptide, CD19+ B cells, immunopathogenesis, newly diagnosed type 1 diabetes, HbA1c, insulin dose
- MeSH terms
- Rituximab, Adolescent, Adult, Antibodies, Monoclonal, B-Lymphocytes, C-Peptide, Child, Diabetes Mellitus, Type 1, Double-Blind Method, Female, Glycated Hemoglobin, Humans, Immunoglobulin M, Immunologic Factors, Male, Area Under Curve, Insulin-Secreting Cells, Young Adult, Antibodies, Monoclonal, Murine-Derived
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
